Herbalife initiated with a Buy at Maxim
Maxim analyst Anthony Vendetti initiated coverage of Herbalife (HLF) with a Buy rating and $20 price target A turnaround is underway, enabling Herbalife to solidify its status as a leading provider of health and wellness products, the analyst tells investors in a research note. Maxim believes the U.S. regulatory concerns are resolved, and the resulting changes, including closer alignment of distributor compensation with sales to end users, have established a more sustainable business model.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HLF:
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.